PACTR202404654347323
Not yet recruiting
未知
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in Mozambique
ConditionsPoliovirus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Poliovirus
- Sponsor
- World Health Organization
- Enrollment
- 888
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •?Healthy child aged 6\-59 months old
- •?Resident in study area for the duration of the study period
- •?Parent/guardian consent for participation in the study
- •?Child included in nOPV2 study or their brothers, cousins, neighbour children
Exclusion Criteria
- •?Health issue contraindication for venepuncture
- •?Acutely sick child or child requiring hospitalization.
- •?Diagnosis or suspicion of congenital immunodeficiency disorder in the subject or an immediate family member
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaJPRN-UMIN000014703The University of Tokyo Hospital15
Completed
Not Applicable
Safety, efficacy and immunogenicity of concomitant interferon alpha and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaRenal cell carcinomaJPRN-UMIN000006646The University of Tokyo Hospital15
Active, not recruiting
Phase 1
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-004118-12-ATMedical University of Vienna256
Completed
Phase 4
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adultsYellow fever, Measles and RubellaJPRN-UMIN000042738Tokyo Medical University Hospital Travellers' Medical Center14
Recruiting
Phase 4
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adultsPrevention of Yellow fever, Measles and RubellaYellow fever, Measles, RubellaJPRN-jRCT1031210111FUKUSHIMA SHINJI20